Related Experiment Videos
Risk factors for development of flucloxacillin associated jaundice
C K Fairley1, J J McNeil, P Desmond
1Department of Social and Preventive Medicine, Monash University, Alfred Hospital, Melbourne, Victoria, Australia.
BMJ (Clinical Research Ed.)
|January 23, 1993
Summary
Older patients and those on prolonged flucloxacillin treatment face a higher risk of developing jaundice. Careful risk-benefit assessment is crucial for these individuals when prescribing flucloxacillin.
Area of Science:
- Hepatology
- Clinical Pharmacology
- Drug Safety
Background:
- Flucloxacillin is a commonly prescribed antibiotic.
- Drug-induced liver injury is a significant concern.
- Identifying risk factors for flucloxacillin-associated jaundice is essential for patient safety.
Purpose of the Study:
- To determine the predisposing risk factors for flucloxacillin-associated jaundice.
- To inform clinical practice regarding the safe use of flucloxacillin.
Main Methods:
- A case-control study design was employed.
- Medical records of patients who developed jaundice after flucloxacillin and controls were reviewed.
- Data collected included demographics, medical history, flucloxacillin treatment details, and other medications.
Main Results:
- Increasing age and longer duration of flucloxacillin treatment (over 14 days) were identified as significant risk factors for jaundice.
- Patients over 55 years old had a substantially higher odds ratio for developing jaundice.
- Neither the dose nor the route of flucloxacillin administration was associated with increased jaundice risk.
Conclusions:
- Older individuals and those treated with flucloxacillin for more than two weeks are at increased risk of developing jaundice.
- Clinicians should carefully weigh the risks and benefits before prescribing flucloxacillin to these patient groups.